This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Primary Hyperoxaluria
  • /
  • Molecular basis of primary hyperoxaluria: clues to...
Journal

Molecular basis of primary hyperoxaluria: clues to innovative treatments

Read time: 1 mins
Published:31st Jan 2019
Author: Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B.
Source: Urolithiasis
Ref.:Urolithiasis. 2019 Feb;47(1):67-78.
DOI:10.1007/s00240-018-1089-z
Molecular basis of primary hyperoxaluria: clues to innovative treatments


Primary hyperoxalurias (PHs) are rare inherited disorders of liver glyoxylate metabolism, characterized by the abnormal production of endogenous oxalate, a metabolic end-product that is eliminated by urine. The main symptoms are related to the precipitation of calcium oxalate crystals in the urinary tract with progressive renal damage and, in the most severe form named Primary Hyperoxaluria Type I (PH1), to systemic oxalosis. The therapies currently available for PH are either poorly effective, because they address the symptoms and not the causes of the disease, or highly invasive. In the last years, advances in our understanding of the molecular bases of PH have paved the way for the development of new therapeutic strategies. They include (i) substrate-reduction therapies based on small-molecule inhibitors or the RNA interference technology, (ii) gene therapy, (iii) enzyme administration approaches, (iv) colonization with oxalate-degrading intestinal microorganisms, and, in PH1, (v) design of pharmacological chaperones. This paper reviews the basic principles of these new therapeutic strategies and what is currently known about their application to PH.


Read abstract on library site Access full article